IGF-1

IGF-1

SST (Tiger Top)

Plasma specimen

Diagnosing growth disorders
Diagnosing adult growth hormone deficiency
Monitoring of recombinant human growth hormone treatment
Insulin-like growth factor binding protein 3 can be used as a possible adjunct to insulin-like growth factor 1 and growth hormone in the diagnosis and follow-up of acromegaly and gigantism.

Male:
≤ 189 ng/mL (≤ 3 years)
47 – 231 ng/mL (4 – 6 years)
55 – 222 ng/mL (7 – 9 years)
95 – 315 ng/mL (10 – 11 years)
95 – 460 ng/mL (12 – 13 years)
211 – 512 ng/mL (14 – 15 years)
57 – 426 ng/mL (16 – 18 years)
105 – 346 ng/mL (19 – 21 years)
107 – 367 ng/mL (22 – 24 years)
88 – 537 ng/mL (25 – 29 years)
41 – 246 ng/mL (30 – 34 years)
57 – 241 ng/mL (35 – 39 years)
43 – 209 ng/mL (40 – 44 years)
74 – 196 ng/mL (45 – 49 years)
55 – 248 ng/mL (50 – 54 years)
36 – 200 ng/mL (55 – 59 years)
51 – 187 ng/mL (60 – 64 years)
37 – 219 ng/mL (65 – 69 years)
24 – 200 ng/mL (70 – 79 years)
17 – 323 ng/mL (80 – 100 years)

Female:
≤ 272 ng/mL (≤ 3 years)
55 – 248 ng/mL (4 – 6 years)
80 – 233 ng/mL (7 – 9 years)
96 – 545 ng/mL (10 – 11 years)
147 – 549 ng/mL (12 – 13 years)
208 – 444 ng/mL (14 – 15 years)
176 – 429 ng/mL (16 – 18 years)
105 – 346 ng/mL (19 – 21 years)
107 – 367 ng/mL (22 – 24 years)
88 – 537 ng/mL (25 – 29 years)
41 – 246 ng/mL (30 – 34 years)
57 – 241 ng/mL (35 – 39 years)
43 – 209 ng/mL (40 – 44 years)
74 – 196 ng/mL (45 – 49 years)
55 – 248 ng/mL (50 – 54 years)
36 – 200 ng/mL (55 – 59 years)
51 – 187 ng/mL (60 – 64 years)
37 – 219 ng/mL (65 – 69 years)
24 – 200 ng/mL (70 – 79 years)
17 – 323 ng/mL (80 – 100 years)